Frauenheilkunde up2date 2013; 7(3): 223-234
DOI: 10.1055/s-0032-1325059
Geburtshilfe und Perinatalmedizin
Georg Thieme Verlag KG Stuttgart · New York

Die Frühgeburt – Prävention, Diagnose und Interventionen

H. Helmer
Further Information

Publication History

Publication Date:
05 July 2013 (online)

Kernaussagen

Die Ursache einer spontanen Frühgeburt ist meist multifaktoriell und umfasst beeinflussbare und nicht beeinflussbare Risikofaktoren. Präventiven Einfluss auf die Frühgeburtenrate haben Maßnahmen zum Infektionsscreening, aber auch die intramuskuläre oder vaginale Applikation von Progesteronpräparaten. Zur Diagnostik bei symptomatischen Patientinnen eignen sich vaginalsonografische Verfahren zur Messung der Zervixlänge sowie die Bestimmung des fetalen Fibronektins im Vaginalsekret bzw. die Kombination der beiden Methoden. Bei bestehender Zervixinsuffizienz und stark verkürzter Zervix (< 15 mm) kann eine Cerclage indiziert sein. Droht eine Frühgeburt nach der 23. SSW, sind Maßnahmen zur Tokolyse für die Dauer von 48 h gefordert, um die fetale Lunge reifen zu lassen. Im Zeitraum bis 24 h vor einer wahrscheinlichen Frühgeburt hat sich Magnesiumsulfat als effektive neuroprotektive Maßnahme erwiesen. Peripartale Antibiotikagaben verringern das Risiko einer neonatalen Gruppe-B-Streptokokken-Infektion.

 
  • Literatur

  • 1 Beck S, Wojdyla D, Say L et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 2010; 88: 31-38
  • 2 Helmer H. Leitlinien zum Management der drohenden Frühgeburt bei Einlings- und Zwillingsschwangerschaft. Consensusmeeting 8.–9. November 2002, Pöllauberg, Stmk. 1. Update Meeting 28. April 2005, Wien. Speculum – Zeitschrift für Gynäkologie und Geburtshilfe 2006; 24: 18-24
  • 3 Keirse MJNC. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990; 97: 149-154
  • 4 Meis PJ, Klebanoff M, Thom E et al. for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
  • 5 Fonseca EB, Celik E, Parra M et al. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357: 462-469
  • 6 Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. Br Med J 2004; 329: 371
  • 7 Berghella V, Baxter JK, Hendrix NW. Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev 2013; (1) CD007235
  • 8 Abbott DS, Radford SK, Seed PT et al. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am J Obstet Gynecol 2013; 208: 122.e1-e6
  • 9 http://www.studies-obsgyn.nl/eufis/index.asp
  • 10 DeFranco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm labor: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am J Obstet Gynecol 2013; 208: 233.e1-6
  • 11 Owen J, Hankins G, Iams JD et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009; 201: 375.e1
  • 12 Berghella V, Rafael TJ, Szychowski JM et al. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 2011; 117: 663-671
  • 13 Alfirevic Z, Stampalija T, Roberts D, Jorgensen AL. Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. Cochrane Database Syst Rev 2012; (4) CD008991
  • 14 MRC/RCOG Working Party on Cervical Cerclage. Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicentre randomised trial of cervical cerclage. Br J Obstet Gynaecol 1993; 100: 516-523
  • 15 de Heus R, Mol BW, Erwich JJ et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. Br Med J 2009; 338: b744
  • 16 The Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. Br J Obstet Gynaecol 2001; 108: 133-142
  • 17 Valenzuela GJ, Sanchez-Ramos L, Romero R et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 2000; 182: 1184-1190
  • 18 Mercer BM, Merlino AA. Society for Maternal-Fetal Medicine. Magnesium sulfate for preterm labor and preterm birth. Obstet Gynecol 2009; 114: 650-668
  • 19 Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 204: 134.e1
  • 20 Bracero LA, Leikin E, Kirshenbaum N, Tejani N. Comparison of nifedipine and ritodrine for the treatment of preterm labor. Am J Perinatol 1991; 8: 365-369
  • 21 Carlo WA, McDonald SA, Fanaroff AA et al. for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks gestation. J Am Med Assoc 2011; 306: 2348-2358
  • 22 Stutchfield P et al. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. Br Med J 2005; 331: 662-664
  • 23 Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; (3) CD004454
  • 24 Lee BH, Stoll BJ, McDonald SA et al. National Institute of Child Health and Human Development Neonatal Research Network. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006; 117: 1503-1510
  • 25 Lee M-J, Guinn D, Lockwood CJ. Antenatal use of corticosteroids in women at risk for preterm delivery. UpToDate 2012
  • 26 Crowther CA, Haslam RR, Hiller JE et al. Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006; 367: 1913-1919
  • 27 Doyle LW, Crowther CA, Middleton P et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (1) CD004661
  • 28 ACOG Committee Opinion No. 475: Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2011; 117: 422-424
  • 29 Crowther CA, Hiller JE, Doyle LW et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. J Am Med Assoc 2003; 290: 2669
  • 30 American College of Obstetricians and Gynecologists Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 2010; 115: 669-671
  • 31 Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010. MMWR 2010; 5 No. RR-10
  • 32 Yancey MK, Schuchat A, Brown LK et al. The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet Gynecol 1996; 88: 811-815